Advanced PET/MR Imaging for Breast Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of the study is to see if a new group of imaging tests can help identify response to stage IV HER2+ breast cancer before treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
Is 2-[18F]-FDG safe for use in humans?
How does the Advanced PET/MR Imaging treatment differ from other breast cancer treatments?
Advanced PET/MR Imaging for breast cancer is unique because it combines PET and MRI technologies to provide detailed images of both the metabolic activity and the structure of tumors, which can help in detecting skeletal metastases and understanding tumor heterogeneity. This approach offers more comprehensive diagnostic information compared to traditional imaging methods, potentially leading to more personalized treatment plans.678910
What data supports the effectiveness of the treatment 2-deoxy-2-[18F]fluoro-D-glucose for breast cancer?
Research shows that 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) can provide important information about breast cancer tumors, such as their glucose metabolism, which is linked to patient outcomes like survival and risk of metastasis. This imaging technique helps doctors understand the tumor better and tailor treatments for breast cancer patients.59111213
Who Is on the Research Team?
Anna Sorace, PhD
Principal Investigator
University of Alabama at Birmingham
Are You a Good Fit for This Trial?
This trial is for adults aged 18-75 with Stage IV HER2+ breast cancer who haven't started a new HER2-targeted therapy. They must have measurable disease, an expected lifespan over six months, and can be estrogen/progesterone receptor positive or negative. Excluded are those with certain medical conditions, metal in their body incompatible with MRIs, pregnant/breastfeeding women, and anyone unable to lie still for imaging.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Imaging
Baseline imaging using PET/MRI to establish initial metrics
Treatment Monitoring
Participants undergo imaging up to three times during therapy to monitor response
Follow-up
Participants are monitored for changes in imaging metrics and disease progression
What Are the Treatments Tested in This Trial?
Interventions
- [18F]-FDG
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor